Subclinical Ventricular Dysfunction Detected by Speckle Tracking Two Years after Use of Anthracycline

Background: Heart failure is a severe complication associated with doxorubicin (DOX) use. Strain, assessed by two-dimensional speckle tracking (2D-STE), has been shown to be useful in identifying subclinical ventricular dysfunction. Objectives: a) To investigate the role of strain in the identification of subclinical ventricular dysfunction in patients who used DOX; b) to investigate determinants of strain response in these patients. Methods: Cross-sectional study with 81 participants: 40 patients who used DOX ±2 years before the study and 41 controls. All participants had left ventricular ejection fraction (LVEF) ≥55%. Total dose of DOX was 396mg (242mg/ms2). The systolic function of the LV was evaluated by LVEF (Simpson), as well as by longitudinal (εLL), circumferential (εCC), and radial (εRR) strains. Multivariate linear regression (MLR) analysis was performed using εLL (model 1) and εCC (model 2) as dependent variables. Results: Systolic and diastolic blood pressure values were higher in the control group (p < 0.05). εLL was lower in the DOX group (-12.4 ±2.6%) versus controls (-13.4 ± 1.7%; p = 0.044). The same occurred with εCC: -12.1 ± 2.7% (DOX) versus -16.7 ± 3.6% (controls; p < 0.001). The S’ wave was shorter in the DOX group (p = 0.035). On MLR, DOX was an independent predictor of reduced εCC (B = -4.429, p < 0.001). DOX (B = -1.289, p = 0.012) and age (B = -0.057, p = 0.029) were independent markers of reduced εLL. Conclusion: a) εLL, εCC and the S’ wave are reduced in patients who used DOX ±2 years prior to the study despite normal LVEF, suggesting the presence of subclinical ventricular dysfunction; b) DOX was an independent predictor of reduced εCC; c) prior use of DOX and age were independent markers of reduced εLL.

Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation

AbstractBackground:Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy.Objective:To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy.Methods:The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased.Results:A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation.Conclusion:In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5).

Heart Failure with Preserved Left Ventricular Ejection Fraction in Patients with Acute Myocardial Infarction

AbstractBackground:The prevalence and clinical outcomes of heart failure with preserved left ventricular ejection fraction after acute myocardial infarction have not been well elucidated.Objective:To analyze the prevalence of heart failure with preserved left ventricular ejection fraction in acute myocardial infarction and its association with mortality.Methods:Patients with acute myocardial infarction (n = 1,474) were prospectively included. Patients without heart failure (Killip score = 1), with heart failure with preserved left ventricular ejection fraction (Killip score > 1 and left ventricle ejection fraction ≥ 50%), and with systolic dysfunction (Killip score > 1 and left ventricle ejection fraction < 50%) on admission were compared. The association between systolic dysfunction with preserved left ventricular ejection fraction and in-hospital mortality was tested in adjusted models.Results:Among the patients included, 1,256 (85.2%) were admitted without heart failure (72% men, 67 ± 15 years), 78 (5.3%) with heart failure with preserved left ventricular ejection fraction (59% men, 76 ± 14 years), and 140 (9.5%) with systolic dysfunction (69% men, 76 ± 14 years), with mortality rates of 4.3%, 17.9%, and 27.1%, respectively (p < 0.001). Logistic regression (adjusted for sex, age, troponin, diabetes, and body mass index) demonstrated that heart failure with preserved left ventricular ejection fraction (OR 2.91; 95% CI 1.35–6.27; p = 0.006) and systolic dysfunction (OR 5.38; 95% CI 3.10 to 9.32; p < 0.001) were associated with in-hospital mortality.Conclusion:One-third of patients with acute myocardial infarction admitted with heart failure had preserved left ventricular ejection fraction. Although this subgroup exhibited more favorable outcomes than those with systolic dysfunction, this condition presented a three-fold higher risk of death than the group without heart failure. Patients with acute myocardial infarction and heart failure with preserved left ventricular ejection fraction encounter elevated short-term risk and require special attention and monitoring during hospitalization.

Diagnosis of Rejection by Analyzing Ventricular Late Potentials in Heart Transplant Patients

Background: Heart transplant rejection originates slow and fragmented conduction. Signal-averaged ECG (SAECG) is a stratification method in the risk of rejection. Objective: To develop a risk score for rejection, using SAECG variables. Methods: We studied 28 transplant patients. First, we divided the sample into two groups based on the occurrence of acute rejection (5 with rejection and 23 without). In a second phase, we divided the sample considering the existence or not of rejection in at least one biopsy performed on the follow-up period (rejection pm1: 18 with rejection and 10 without). Results: On conventional ECG, the presence of fibrosis was the only criterion associated with acute rejection (OR = 19; 95% CI = 1.65-218.47; p = 0.02). Considering the rejection pm1, an association was found with the SAECG variables, mainly with RMS40 (OR = 0.97; 95% CI = 0.87-0.99; p = 0.03) and LAS40 (OR = 1.06; 95% IC = 1.01-1.11; p = 0.03). We formulated a risk score including those variables, and evaluated its discriminative performance in our sample. The presence of fibrosis with increasing of LAS40 and decreasing of RMS40 showed a good ability to distinguish between patients with and without rejection (AUC = 0.82; p < 0.01), assuming a cutoff point of sensitivity = 83.3% and specificity = 60%. Conclusion: The SAECG distinguished between patients with and without rejection. The usefulness of the proposed risk score must be demonstrated in larger follow-up studies.

O eletrocardiograma na fase crônica da doença de Chagas experimental no cão

O Autor estudou o eletrocardiograma de 6 cães adultos antes e após a inoculação, nestes animais, de uma amostra de Schizotrypanum cruzi obtida de um caso humano de miocardite chagásica com bloqueio aurículo-ventricular total. A fase aguda da moléstia nos cães foi seguida por frequentes exames de sangue a fresco, entre lãmina e lamínula, para a pesquisa do flagelado. Os traçados eletrocardiográficos foram obtidos antes da inoculação e até 320 dias após a mesma. Além das derivações periféricas, em alguns cães, registrou também as derivações precordiais. A interpretação dos eletrocardiogramas seriados foi feita levando-se em conta a variabilidade dos traçados em série observada em cães normais. Em todos os 6 cães estudados houve uma diminuição muito acentuada da voltagem dos complexos ventriculares, denotando lesão miocárdica. A diminuição da voltagem de QRs já se evidencia na fase aguda e de transição da moléstia, tornando-se máxima logo no inicio da fase crônica. Em dois cães, paralelamente com a diminuição da voltagem, houve uma rotação do eixo elétrico para a esquerda. Em um cão foram observadas extrasístoles ventriculares e, em dois, extrasístoles auriculares. Somente em um cão observou alterações significativas da onda P. constituidas por alargamento e entalhe da mesma. O Autor salienta e discute o fato de não ter encontrado alterações na condução (não houve aumento de Pr e somente em um caso houve alargamento significativo de QRS). As pesquizas ainda continuam sendo apenas parciais os resultados apresentados. Agradecemos ao Prof. AMERICANO FREIRE pelas sugestões e ao Sr. KURT BENSEMANN pela constante assistencia técnica.

Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy

Global left ventricular (LV) systolic dysfunction is the strongest predictor of morbidity and mortality in Chagas disease. Echocardiography is considered the gold standard for the detection of LV dysfunction, but not always available in endemic areas where chagasic cardiomyopathy is most common. Brain natriuretic peptide (BNP) is a neurohormone that has been recently described as a simple and inexpensive diagnostic and prognostic marker for patients with congestive heart failure. Chagasic patients (n = 63) and non-infected healthy individuals (n = 18) were recruited prospectively and underwent complete clinical examination, echocardiography and 24-h Holter monitoring. BNP was measured from thawed plasma samples using the Triage BNP test. We observed high levels of BNP in association with depression of LV ejection fraction, with increase of LV end-diastolic diameter and with LV premature complexes. An elevated concentration of BNP, defined as a concentration of 60 pg/ml or more, had a sensitivity of 91.7%, specificity of 82.8%, positive predictive value of 52.4%, and negative predictive value of 98% for detecting LV dysfunction (LV ejection fraction < 40%).BNP measurement using a simple, relatively inexpensive and rapid test has a promising role in identifying LV dysfunction associated with chagasic cardiomyopathy. Equally important, patients with Trypanosoma cruzi infection who have low levels of BNP level in plasma have a very low likelihood of severe cardiac involvement, and echocardiography is probably not necessary.

Efeito da somatotropina na hipertrofia das fibras musculares esqueléticas e precocidade reprodutiva de novilhas Nelore

O trabalho objetivou avaliar o desempenho produtivo, precocidade sexual e hipertrofia das fibras musculares esqueléticas em resposta à aplicação de somatotropina bovina recombinante (rbST). Foram utilizadas 58 novilhas Nelore de sete meses de idade com peso vivo médio de 193 kg. O delineamento experimental foi inteiramente casualizado, em um esquema fatorial incompleto e dividido em duas fases experimentais. Na primeira fase, com duração de 150 dias, os animais foram divididos em dois grupos, de acordo com os níveis de rbST, 0 mg (controle) e 500 mg, a cada 28 dias. Na Fase II, os animais do grupo controle da Fase I foram divididos em 15 e 14 novilhas, que receberam 0 mg e 500 mg de rbST, respectivamente; os animais tratados com 500 mg na Fase I foram divididos em 15 e 14 novilhas e receberam 500 mg e 1.000 mg de rbST, respectivamente, com intervalos de 28 dias, e dieta em regime de pastejo, durante 180 dias. Foram retirados fragmentos do músculo semitendinosus para análise das fibras, no início e final da Fase I. Os animais foram pesados a cada 28 dias. Os resultados mostraram que não houve diferença significativa (p>0,05) entre os tratamentos quanto ao ganho de peso e quanto à precocidade sexual. Quanto ao diâmetro das fibras, os animais que receberam rbST tiveram um aumento significativo (p<0,01) tanto nas fibras de contração lenta quanto nas fibras de contração rápida em relação aos animais-controle.

Veia cava superior esquerda anômala com ausência de veia cava superior direita: achados de imagem

A persistência da veia cava superior esquerda com ausência da veia cava superior direita é uma anomalia rara, com menos de 150 casos descritos na literatura. A não-obliteração e regressão da veia cardinal anterior esquerda durante o desenvolvimento embriológico promove uma variação sistêmica de retorno venoso ao coração, com persistência da veia cava superior esquerda. Sua incidência varia de 0,3% em pacientes sem alterações cardíacas congênitas concomitantes a 4,3% naqueles com cardiopatias. Na maioria das vezes coexiste a veia cava superior direita, porém se houver regressão e degeneração da veia cardinal anterior direita, implicará a sua ausência e a drenagem venosa para o coração será feita pela veia cava superior esquerda ao átrio direito, através do seio coronariano. Mostramos um caso de um paciente submetido a radiografia de tórax e tomografia computadorizada para avaliação de doença pulmonar obstrutiva crônica, tendo como achado a persistência da veia cava superior esquerda com ausência da direita, sem qualquer cardiopatia associada e com a drenagem cardíaca sendo feita, através do seio coronariano, para o átrio direito.

Arco aórtico direito com artéria subclávia esquerda aberrante e divertículo de Kommerell

É relatado um caso de uma paciente do sexo feminino, 40 anos de idade, com queixas de disfagia e dor torácica retroesternal há três anos causadas pela presença de artéria subclávia esquerda aberrante retroesofágica com origem em uma dilatação aneurismática (divertículo de Kommerell). O arco aórtico e a aorta torácica descendente estão localizados à direita. O diagnóstico foi estabelecido por meio dos exames de esofagograma, tomografia computadorizada e angiorressonância magnética. A paciente apresentou melhora importante com o tratamento clínico e, atualmente, segue em acompanhamento ambulatorial há um ano.